AHA 2020 - Heart Failure Classification for Appropriate Device Therapy and GDMT

November 20, 2020

In this video, Dr. William Abraham discusses the overwhelming presence of Heart Failure globally. The clinical evidence points to the subjectivity of classifying heart failure functional class however this diagnosis is extremely important for treatment plans.  Dr. Jagmeet Singh discusses current device options in addition to GDMT to help patients that continue to suffer from symptoms.  Dr. Singh discusses the benefits of CCM® therapy for patients with NYHA Class III, EF 25 - 45%, that remain symptomatic despite being treated with Guideline Directed Medical Therapy and that are NOT indicated for Cardiac Resynchronization Therapy.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login